7 Recommendations for further research

7.1

The committee noted that there were limitations and uncertainties in the evidence presented for migalastat. It encourages the company, NHS England and treatment centres to collect more evidence, particularly on the longer-term benefits and costs of migalastat and enzyme replacement therapy (ERT) for treating Fabry disease.